A recent JavaWorld Community forum message (Stack Overflow after instantiating new object) reminded me that the basics of the StackOverflowError are not always ...

10 stocks we like better than Recursion Pharmaceuticals › Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly ...

It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced a research agreement with Sanofi Genzyme, the specialty care global business unit of Sanofi, to deploy its drug repurposing ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...